Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
On August 5, 2013, the following individuals purchased Ordinary Shares at a price of 1,722 pence per share. These purchases resulted from the re-investment of dividends on shares held within an Individual Savings Account (ISA):
- Sir Andrew Witty: 49 shares
- Mr S M Bicknell: 84 shares
- Mr D S Redfern: 15 shares
- Mrs V A Whyte: 13 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: August 5, 2013
- Share Price: 1,722 pence per Ordinary Share
- Transaction Type: Dividend re-investment within an ISA
- Participants: Four senior executives/directors (Witty, Bicknell, Redfern, Whyte)
- Notification Date: August 6, 2013